3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs​.

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]

No animal studies have been reported. No application has been made for human clinical trials.[citation needed]

References

  1. ^ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[permanent dead link‍]," The Wall Street Journal, August 4, 2010
  2. ^ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010
  3. ^ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)


Allikas: https://en.wikipedia.org/wiki/GSK_299423
No tags for this post.